Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 9 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal · at its 52-week low
| 1.65 | 52-week high | +1168.26% |
| 0.3800 | Previous month high | +192.08% |
| 0.2200 | Previous month low | +69.10% |
| 0.1700 | Previous week high | +30.67% |
| 0.1467 | R3 (classic) | +12.73% |
| 0.1433 | R2 (classic) | +10.17% |
| 0.1400 | Previous day high | +7.61% |
| 0.1367 | R1 (classic) | +5.05% |
| 0.1333 | Pivot | +2.49% |
| 0.1301 | Price now | |
| 0.1300 | Previous day low | −0.08% |
| 0.1300 | Previous week low | −0.08% |
| 0.1300 | 52-week low | −0.08% |
| 0.1267 | S1 (classic) | −2.64% |
| 0.1233 | S2 (classic) | −5.20% |
| 0.1167 | S3 (classic) | −10.33% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $532.4K | 0.00% | 2.07M | −9.9% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ARAY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Pervaiz AliChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 19.8K | — |
| Feb 26, 2026 | Peralta LeonelChief Operating Officer | — | 83.7K | — |
| Feb 19, 2026 | Mayer Steven FDirector | Purchase at price 0.56 per share. | 54.9K | $30.88K |
| Feb 18, 2026 | Mayer Steven FDirector | Purchase at price 0.53 per share. | 195.1K | $103.80K |
| Dec 30, 2025 | Scott Byron CDirector | — | 9.4K | — |
| Nov 27, 2025 | Chalke SandeepOfficer | — | 50.3K | — |
| Nov 27, 2025 | Pervaiz AliChief Financial Officer | — | 44K | — |
| Nov 27, 2025 | Mayer Steven FDirector | Stock Award(Grant) at price 0.00 per share. | 895.4K | — |
| Nov 27, 2025 | Galbato Chan WDirector | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Nov 20, 2025 | Le Grand Anne BryceDirector | — | 56.6K | — |
| Nov 20, 2025 | Scott Byron CDirector | — | 56.6K | — |
| Nov 20, 2025 | Nishimura MikaDirector | — | 56.6K | — |
| Nov 20, 2025 | Whitters Joseph EDirector | — | 56.6K | — |
| Nov 20, 2025 | Mayer Steven FDirector | — | 45.6K | — |
| Nov 20, 2025 | Hindman James MDirector | — | 56.6K | — |
| Nov 20, 2025 | Huss Beverly ADirector | — | 56.6K | — |
| Nov 18, 2025 | La Neve Stephen RChief Executive Officer | Purchase at price 0.97 per share. | 20K | $19.41K |
| Nov 12, 2025 | Kill Robert CDirector | — | 56.6K | — |
| Oct 30, 2025 | Murphy Michael JohnOfficer | — | 37.5K | — |
| Oct 30, 2025 | Mayer Steven FDirector | Stock Award(Grant) at price 0.00 per share. | 354.6K | — |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.2 | -28.4 | -32.8 | 20.5 | -19.1 | -31.6 | 3.8 | -3.7 | 3.8 | -51.8 | −84.1% | ||
| 2025 | 12.6 | -9.9 | -10.9 | -13.4 | -1.3 | -10.5 | -4.4 | 16.0 | 9.9 | -15.6 | -23.4 | -24.1 | −58.6% |
| 2024 | -8.5 | 0.4 | -5.0 | -13.8 | -16.9 | 2.8 | 1.1 | 18.5 | -17.4 | -3.9 | 28.9 | -11.2 | −30.0% |
| 2023 | 20.6 | 15.1 | 2.4 | 12.5 | 10.5 | 4.9 | 10.1 | -33.1 | -4.6 | -2.9 | -1.1 | 8.4 | +35.4% |
| 2022 | -23.5 | -4.9 | -4.6 | -19.6 | -21.8 | -5.8 | 7.1 | 13.3 | -12.6 | -1.9 | 0.5 | 2.0 | −56.2% |
| 2021 | 18.5 | 0.8 | -0.6 | -5.1 | -9.4 | 6.1 | -9.3 | -0.7 | -2.9 | 26.3 | -3.6 | -0.8 | +14.4% |
| 2020 | 37.9 | -23.7 | -36.0 | 17.9 | -6.3 | -3.3 | 9.9 | 4.5 | 3.0 | 21.2 | 53.3 | -6.5 | +47.9% |
| 2019 | 29.0 | 9.5 | -1.0 | -13.2 | -10.4 | 4.3 | 7.0 | -35.3 | 3.4 | -6.1 | 18.5 | -8.4 | −17.3% |
| 2018 | 31.4 | -1.8 | -9.9 | 0.0 | -12.0 | -6.8 | -6.1 | 3.9 | 12.5 | -0.2 | -8.7 | -16.8 | −20.7% |
| 2017 | 25.0 | -10.4 | -7.8 | -4.2 | -9.9 | 15.9 | -10.5 | -2.4 | -3.6 | 18.8 | 8.4 | -16.5 | −6.5% |
| 2016 | -21.0 | -5.3 | 14.5 | -7.3 | 1.7 | -4.8 | 5.6 | -2.7 | 19.5 | -23.1 | 3.1 | -8.9 | −31.9% |
| 2015 | -2.4 | 21.8 | 3.6 | -12.6 | -24.4 | 9.6 | -5.3 | 8.0 | -27.4 | 34.0 | 5.1 | -4.1 | −10.6% |
| 2014 | 22.4 | -11.9 | 2.3 | -12.5 | 5.0 | -0.2 | -10.6 | 3.4 | -10.8 | -12.8 | 8.8 | 9.6 | −13.2% |
| 2013 | -20.5 | -16.4 | 8.7 | -5.2 | 22.3 | 6.7 | 8.2 | 6.6 | 11.5 | -8.4 | 18.0 | 9.0 | +35.3% |
| 2012 | 33.6 | 20.0 | 4.1 | 9.1 | -18.6 | 8.8 | -7.5 | -2.9 | 15.5 | -1.7 | -9.8 | 2.4 | +52.0% |
| 2011 | 26.8 | 15.7 | -8.9 | -1.4 | -14.1 | 4.8 | -13.9 | -28.4 | -18.8 | -0.2 | 0.3 | 5.5 | −37.3% |
| 2010 | 5.9 | 14.0 | -10.3 | 5.9 | -5.1 | 8.7 | -0.8 | 0.0 | -5.5 | 5.8 | -9.1 | 12.9 | +20.3% |
| 2009 | 19.8 | -24.4 | 7.7 | 20.3 | 1.8 | 7.8 | 5.6 | -8.6 | 1.4 | -11.2 | -10.4 | 8.5 | +8.7% |
| 2008 | -37.5 | 8.8 | -24.6 | 0.3 | 22.1 | -23.7 | 17.1 | -3.4 | -2.2 | -21.7 | -20.1 | 2.2 | −66.1% |
| 2007 | -12.7 | 6.1 | -2.5 | -3.6 | -14.7 | -26.9 | 26.2 | 15.1 | -17.4 | -8.4 | −40.3% |
No analyst coverage for this instrument.
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.